Global Pruritus Therapeutics Market Overview
Pruritus Therapeutics Market accounted for USD 3.85 Billion in 2019 and is anticipated to register a CAGR of 12.5%
Pruritus is commonly associated with a primary skin disorder such as atopic dermatitis, xerosis, drug eruption, psoriasis, urticaria, arthropod assault, dermatitis herpetiformis, and mastocytosis. The skin disorder results in an unpleasant sensation that provokes the desire to itch or scratch. Pruritus has long been associated with certain systemic diseases, and it ranges in intensity from mild itchiness to an insistent, disabling condition. On the basis of the underlying causative disease, generalized pruritus can be classified into cholestatic pruritus, renal pruritus, hematologic pruritus, idiopathic generalized pruritus, endocrine pruritus and pruritus related to malignancy. Chronic pruritus is commonly observed in pregnant women. WHO estimates that almost 900 million people in the world at any time suffer from skin diseases, and they are among the most common of all human health afflictions. In the setting of both cutaneous and systemic conditions, around 23-44 million people in America are likely to suffer from chronic pruritus. Prevalence of chronic pruritus in individuals not only impact their ability to function, but also ranges from mood disturbances, deranged sleep patterns, high levels of anxiety leading to depression, and overall, reduced quality of life.
Global Pruritus Therapeutics Market Drivers & Restraints
The pruritus therapeutics market is growing due to several factors such as, increasing incidence of dermatological disorder influencing the occurrence of pruritus and growing demand for proper diagnostics as well as therapeutics to treat such medical condition. The rising inorganic development strategies, and continuously development of new drugs for the treatment and robust pipeline products are also boosting the growth of the pruritus therapeutic market. Identification of novel T-cell subsets such as Th17 & Th22 and patent expiry of numerous pruritus therapeutic medications such as Protopic (tacrolimus) are also driving the growth of the market. The emerging players have a lucrative opportunity to enter the pruritus therapeutics market, owing to availability of research fundings, and favorable regulatory scenario for external medicines.
However, lack of awareness towards therapeutics for pruritus, and the associated side effects associated with pruritus therapeutics are hindering the growth of the market.
Global Pruritus Therapeutics Market Segmentations & Regional Insights
Pruritus dermatology market is segmented based on the disease type, treatment and region.
Base on the disease type, the global market is segmented into internal diseases, atopic dermatitis, allergic, and others. Atopic Dermatitis is one of the most commonly occurring chronic skin conditions that often begin in early childhood.
On the basis of treatment, the global market is segmented into antihistamines and corticosteroids. Corticosteroids product type held maximum share in the global pruritus market. Corticosteroids are used to treat skin conditions as they suppress inflammation by reducing the amount of collagen production in the skin. It can be applied to the skin in the topical form of ointments, creams, lotions, shampoos, mousses, tapes, or gels. A variety of corticosteroids and other anti-inflammatory creams are available in the market that can be applied to the skin for effective treatment of rashes.
Regional Insights:
According to the region, market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America led the growth of the market majorly on account of the presence of a high prevalence of diseases associated with pruritus, the introduction of new products targeting the unmet medical needs, and growing patient awareness levels. The Asia Pacific pruritus therapeutics market is also expected to grow at a high rate in the coming years. The presence of high unmet healthcare needs and increasing prevalence of allergic contact dermatitis and urticaria in this region are some factors attributing to its rapid growth rate.
Detail Segmentation:
Attribute |
Details |
The base year for estimation |
2019 |
Forecast Period |
2019 - 2034 |
Market Representation |
Revenue in USD Million & CAGR from 2019-2034 |
Market Segmentation |
By Disease Type - Internal Diseases, Atopic Dermatitis, Allergic, and Others By Treatment - Corticosteroids, and Antihistamines By Region - North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Regional Scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report Coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered in the report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2034. For the purpose of this study, has segmented the pruritus therapeutics market report based on disease type, treatment and region.
Global Pruritus Market, By Disease Type
- Internal Diseases
- Atopic Dermatitis
- Allergic
- Others
Global Pruritus Market, By Treatment
- Corticosteroids
- Antihistamines
Global Pruritus Market, By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Global Pruritus Therapeutics Market Competitive Landscape & Key Players
The major players contributing in the market includes Sanofi, Pfizer, Tai Guk Pharmaceutical Company, Actavis, Trevi Therapeutics, Cara Therapeutics, Ocera Therapeutics Inc. and NeRRe Therapeutics, Cipla, Merck.
Global Pruritus Therapeutics Market Company Profile
Global Pruritus Therapeutics Market Highlights
FAQs
The global pruritus dermatology market is segmented based on the disease type, treatment and region.
The global pruritus therapeutics market is growing due to several factors such as, increasing incidence of dermatological disorder influencing the occurrence of pruritus and growing demand for proper diagnostics as well as therapeutics to treat such medical condition.
North America led the growth of the market majorly on account of the presence of a high prevalence of diseases associated with pruritus, the introduction of new products targeting the unmet medical needs, and growing patient awareness levels.
The major players contributing in the market includes Sanofi, Pfizer, Tai Guk Pharmaceutical Company, Actavis, Trevi Therapeutics, Cara Therapeutics, Ocera Therapeutics Inc. and NeRRe Therapeutics, Cipla, Merck.